 previous article in this issue | next article in this issue  |
|
Document Details : Title: Immuun-trombocytopenische purpura Author(s): LOUW VJ Journal: Tijdschrift voor Geneeskunde Volume: 61 Issue: 11 Date: 2005 Pages: 865-868 DOI: 10.2143/TVG.61.11.5002202 Abstract : Immuun-trombocytopenische purpura is een auto-immune afwijking waarbij antistoffen gericht tegen antigenen op het plaatjesoppervlak het verwijderen van plaatjes uit de circulatie door het reticulo-endotheliale stelsel tot gevolg hebben. Immune thrombocytopenic purpura The estimated incidence of ITP is 50-100 cases per million per year, and about half of these occur in children. Immune thrombocytopenic purpura is classified as primary or as secondary to an underlying disorder and as acute or chronic (> 6 months duration). Adult-onset and childhood-onset immune thrombocytopenic purpura are strikingly different. Affected children are young (peak age, approximately five years) and previously healthy, and they typically present with the sudden onset of petechiae or purpura a few days or weeks after an infectious illness or vaccination. In more than 70 percent of children, the illness resolves within six months. By contrast, immune thrombocytopenic purpura in adults is generally chronic, the onset is often insidious, and approximately twice as many women as men are affected. Exclude other causes of thrombocytopenia, such as leukemia, marrow infiltration, myelodysplasia, aplastic anemia, or adverse drug reactions, to establish a diagnosis of ITP. Pseudothrombocytopenia due to platelet clumping also is a diagnostic consideration.ITP is a diagnosis of exclusion and no single laboratory test or clinical finding exists that establishes a diagnosis of ITP. The aim of treatment is not normalizing the platelet count, but maintaining the minimum platelet count to prevent bleeding. |
  |
107.21.186.38.
